(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(0.51%) $78.51
(1.87%) $2.18
(0.10%) $2 310.90
(0.56%) $26.84
(0.10%) $966.30
(-0.35%) $0.929
(-1.42%) $10.84
(-0.12%) $0.797
(0.52%) $91.61
5 days till quarter result
(bmo 2024-05-10)
Expected move: +/- 10.23%
-8.45% $ 2.60
@ $5.43
Wydano: 9 vas. 2024 @ 22:55
Zwrot: -52.12%
Poprzedni sygnał: vas. 7 - 21:00
Poprzedni sygnał:
Zwrot: 5.44 %
Live Chart Being Loaded With Signals
First Wave BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of targeted and non-systemic therapies for the treatment of patients with gastrointestinal diseases...
Stats | |
---|---|
Dzisiejszy wolumen | 45 783.00 |
Średni wolumen | 90 147.00 |
Kapitalizacja rynkowa | 5.27M |
EPS | $0 ( 2024-04-01 ) |
Następna data zysków | ( $-2.18 ) 2024-05-10 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.0500 |
ATR14 | $0.0690 (2.65%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-01 | Sapirstein James | Sell | 174 | Common Stock |
2024-04-01 | Romano Sarah | Sell | 75 | Common Stock |
2024-03-15 | Sapirstein James | Sell | 1 887 | Common Stock |
2024-03-15 | Romano Sarah | Sell | 1 120 | Common Stock |
2024-03-13 | Syage Jack | Buy | 15 400 | Common Stock, par value $0.0001 per share |
INSIDER POWER |
---|
93.59 |
Last 95 transactions |
Buy: 5 900 618 | Sell: 1 318 677 |
Wolumen Korelacja
First Wave BioPharma, Korelacja
10 Najbardziej pozytywne korelacje | |
---|---|
PDSB | 0.826 |
ALLK | 0.815 |
VCSA | 0.815 |
NAKD | 0.811 |
WTBA | 0.81 |
FREE | 0.809 |
LBPS | 0.804 |
LYRA | 0.804 |
TRIT | 0.803 |
CRBU | 0.801 |
10 Najbardziej negatywne korelacje | |
---|---|
BBIO | -0.836 |
NVDA | -0.834 |
LSCC | -0.834 |
ACVA | -0.828 |
PDFS | -0.827 |
BRKS | -0.823 |
OSW | -0.822 |
FTNT | -0.821 |
ADI | -0.821 |
RRGB | -0.82 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
First Wave BioPharma, Korelacja - Waluta/Towar
First Wave BioPharma, Finanse
Annual | 2023 |
Przychody: | $0 |
Zysk brutto: | $-29 274.00 (0.00 %) |
EPS: | $-46.96 |
FY | 2023 |
Przychody: | $0 |
Zysk brutto: | $-29 274.00 (0.00 %) |
EPS: | $-46.96 |
FY | 2022 |
Przychody: | $0 |
Zysk brutto: | $-106 207 (0.00 %) |
EPS: | $-461.72 |
FY | 2021 |
Przychody: | $0.00 |
Zysk brutto: | $0.00 (0.00 %) |
EPS: | $-1 377.25 |
Financial Reports:
No articles found.
First Wave BioPharma,
First Wave BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of targeted and non-systemic therapies for the treatment of patients with gastrointestinal diseases. Its product candidates include niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties; and the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients. The company develops FW-COV, which is in Phase II clinical trials for the treatment of severe acute respiratory syndrome coronavirus 2 gastrointestinal infections; FW-UP, which is in Phase II clinical trials for the treatment ulcerative proctitis and ulcerative proctosigmoiditis; FW-ICI-AC for immune checkpoint inhibitor-associated colitis and diarrhea in advanced stage oncology patients; and FW-UC, which is in Phase Ib/IIa clinical trials for the treatment of ulcerative proctitis and ulcerative proctosigmoiditis. It also develops FW-CD, which has completed Phase I clinical trials for Crohn's disease; and adrulipase, an oral, non-systemic, and biologic capsule for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis. The company was formerly known as AzurRx BioPharma, Inc. and changed its name to First Wave BioPharma, Inc. in September 2021. First Wave BioPharma, Inc. was incorporated in 2014 and is headquartered in Boca Raton, Florida.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej